Zuellig Pharma has announced the acquisition of household names Zam-Buk® and Vapex® from Bayer AG, representing a significant growth milestone in its consumer healthcare portfolio.
ZUELLIG PHARMA ACQUIRES LEADING BRANDS FROM BAYER AG
Zuellig Pharma (Zuellig) – a leader in integrated healthcare solutions across Asia – has strengthened its consumer healthcare offering by acquiring two core brands from Bayer AG’s consumer healthcare division in Thailand, Singapore, Indonesia, Malaysia, and Brunei.
Zuellig has acquired full rights to the consumer healthcare brands Zam-Buk® and Vapex®. The former is known for its antiseptic ointment used to treat serious itches, particularly those caused by allergies and insect bites. First launched in 1902, it has become a staple in over-the-counter medical products.
Vapex® equally stands as a household name in the nasal inhaler space, relieving nasal congestion since 1917 across Thailand and beyond.
Zuellig’s acquisition of the two brands marks an important step in its expansion strategy, as the company aims to reinforce its scale across the Asian consumer health market.
Established over a century ago, Zuellig has become a major player in the commercial healthcare space, operating across 18 markets with over 12,000 staff members. The company boasts an impressive operational footprint, serving over 200,000 medical facilities and 450+ clients with world-class healthcare solutions.
This recent agreement follows the company’s acquisition of Filipino business Propan TLC – a major children’s multivitamin brand – in January last year, underpinning Zuellig’s goal to become a trusted provider of everyday necessities across the region.
John Graham, CEO of Zuellig, has stated that combining the established legacy of Zam-Buk® and Vapex® with the organisation’s forward-looking regional commercial capabilities and local market expertise marks a significant growth milestone.
Zuellig intends to increase its distribution and access across all relevant channels in Asia, ensuring the two brands will continue to be household names and readily available to consumers.
The acquisition builds on Zuellig’s outstanding reputation for industry-leading distribution, commercialisation, and clinical trial support services, which are reinforced by the company’s innovative culture and vision of making healthcare more accessible.
